DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Study of Docetaxel in Combination With Cisplatin and 5-Fluorouracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Information source: Dana-Farber Cancer Institute
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Advanced Squamous Cell Carcinoma; Squamous Cell Carcinoma of Head and Neck; SSCHN

Intervention: Docetaxel (Drug); Cisplatin (Drug); 5-Fluorouracil (Drug)

Phase: Phase 1/Phase 2

Status: Completed

Sponsored by: Dana-Farber Cancer Institute

Official(s) and/or principal investigator(s):
Marshall Posner, MD, Principal Investigator, Affiliation: Dana-Farbar Cancer Institute


The purpose of this study is to determine the appropriate dose, that dose which is found to give maximum effect with limited toxicity, of cisplatin in combination with docetaxel and 5-fluorouracil and then to further define the safety and effectiveness of this combination of medications.

Clinical Details

Official title: Phase I/II Pilot Study of Induction Chemotherapy With Docetaxel in Combination With Cisplatin and 5-Fluorouracil (5-FU) in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

To determine whether cisplatin in combination with docetaxel and 5-fluorouracil can be given with acceptable side effects

to determine the efficacy of said combination.

Secondary outcome: To define the safety profile, the dose limiting toxicity and the recommended dose of cisplatin in combination with docetaxel and 5-fluorouracil.

Detailed description:

- Treatment begins with a one hour infusion of docetaxel followed by a 1/2 hour infusion

of cisplatin. 5-fluorouracil will be administered through continuous IV infusion through a portable pump for four days at home. A cycle is twenty-one days long ( 4 days of chemotherapy and 17 days of recovery).

- During each cycle blood tests will be performed weekly. A physical exam will be

performed and the impact of the chemotherapy will be assessed at the end of each cycle.

- If after 2 cycles the patients cancer has not responded sufficiently they will be

removed from the study.

- If significant reduction in the size of the tumor is observed after cycle 2, a third

and final cycle will be performed. Followed by radiation therapy twice daily for approximately 6-7 weeks.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Histologically or cytologically confirmed diagnosis of squamous cell carcinoma of

head and neck (SSCHN).

- At least one bi- or uni-dimensionally measurable lesion.

- Stage II or IV disease without evidence of distant metastasis.

- No previous chemotherapy, radiotherapy or surgery (other than biopsy) for SSCHN.

- Age greater than 18 years.

- ECOG performance status of 0 or 1.

- Life expectancy of greater than 12 weeks.

- Adequate bone marrow, hepatic and renal function.

- Normal serum calcium

Exclusion Criteria:

- Primary tumor location in nasopharynx, nasal cavity, sinuses, or salivary glands.

- Patients with any non-SSCHN malignancy within 5 years of study entry, except

curatively treated basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the uterine cervix.

- Any prior treatment with chemotherapy.

- Prior radiotherapy to major bone marrow area (> 10% bone marrow) or to head and neck.

- Current peripheral neuropathy of greater than NCI grade 2.

- Other serious illness or medical condition

- Concurrent treatment with corticosteroids unless chronic treatment at low doses.

- Pregnant or lactating females or females of childbearing potential not employing

adequate contraception.

Locations and Contacts

Additional Information

Related publications:

Posner MR, Glisson B, Frenette G, Al-Sarraf M, Colevas AD, Norris CM, Seroskie JD, Shin DM, Olivares R, Garay CA. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2001 Feb 15;19(4):1096-104.

Haddad R, Colevas AD, Tishler R, Busse P, Goguen L, Sullivan C, Norris CM, Lake-Willcutt B, Case MA, Costello R, Posner M. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience. Cancer. 2003 Jan 15;97(2):412-8.

Starting date: February 1998
Last updated: June 2, 2008

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017